Recombinant human bone morphogenetic protein 4 - StemGen

Drug Profile

Recombinant human bone morphogenetic protein 4 - StemGen

Alternative Names: BMP4 - StemGen; hBMP4 - StemGen; hrBMP4 - StemGen

Latest Information Update: 17 Aug 2016

Price : $50

At a glance

  • Originator StemGen
  • Class Bone morphogenetic proteins; Calcium regulators; Recombinant proteins
  • Mechanism of Action Bone morphogenetic protein receptor type I modulators; Bone morphogenetic protein receptor type II modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioblastoma
  • Suspended Colorectal cancer

Most Recent Events

  • 11 Aug 2016 Stemgen plans a phase I trial for Glioblastoma (Recurrent, Late-stage disease, Second-line therapy or greater) in Israel, Germany, Italy and Netherlands (Intratumoural) (NCT02869243)
  • 08 Aug 2016 Suspended - Preclinical for Colorectal cancer in Italy (unspecified route)
  • 08 Aug 2016 Recombinant human bone morphogenetic protein 4 is still in preclinical trials for Glioblastoma in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top